Expert Review of Cardiovascular Therapy
ISSN: 1477-9072 (Print) 1744-8344 (Online) Journal homepage: http://www.tandfonline.com/loi/ierk20
British Society for Heart Failure 17th Annual Autumn Meeting Parminder S Chaggar To cite this article: Parminder S Chaggar (2015) British Society for Heart Failure 17th Annual Autumn Meeting, Expert Review of Cardiovascular Therapy, 13:2, 141-143 To link to this article: http://dx.doi.org/10.1586/14779072.2015.1000309
Published online: 02 Jan 2015.
Submit your article to this journal
Article views: 32
View related articles
View Crossmark data
Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierk20 Download by: [University of Iowa Libraries]
Date: 05 November 2015, At: 14:01
Meeting Report
British Society for Heart Failure 17th Annual Autumn Meeting Downloaded by [University of Iowa Libraries] at 14:01 05 November 2015
Expert Rev. Cardiovasc. Ther. 13(2), 141–143 (2015)
Parminder S Chaggar North West Heart Centre, University Hospital of South Manchester, Manchester, UK Tel.: 01 619 987 070 [email protected]
British Society for Heart Failure 17th Annual Autumn Meeting QEII Conference Centre, London, UK, 27–28 November 2014 The British Society for Heart Failure recently held its 17th annual meeting in London, attracting over 700 delegates for the 2-day conference. The meeting covered a wide range of topics, including common co-morbidities, diagnostic dilemmas, latest guidelines/clinical trials and managing clinically challenging scenarios. The British Society for Heart Failure meeting provides an entertaining and informative forum to learn from internationally renowned experts in both the field of heart failure and allied specialties. Future meetings are highly recommended.
The British Society for Heart Failure recently held its 17th annual meeting in London, attracting over 700 delegates for the 2-day conference. Entitled ‘Yesterday’s problems, today’s solutions’, the meeting covered a wide range of topics including common co-morbidities, diagnostic dilemmas, problem drugs and a key-note lecture on the development of the artificial heart by Christian Latremouille (Georges Pompidou European Hospital, Paris, France). Of particular note were updates on latest guidelines/clinical trials and managing clinically challenging scenarios. Guidelines & trials update
Theresa McDonagh (King’s College London, UK) presented as yet unpublished data from the latest incarnation of the National Heart Failure Audit which this year includes data from 97% of NHS trusts in England and 100% in Wales. The current audit adds approximately 55,000 heart failure (HF) admissions to the overall audit, which now includes 240,000 admissions. The findings are similar to previous years with approximately 70% of patients diagnosed with left ventricular systolic dysfunction (LVSD) and the proportion of LVSD being higher in men (77% male vs 60% female). Patients with HF with preserved ejection fraction (EF) are more likely to be women and have comorbidities, including
informahealthcare.com
10.1586/14779072.2015.1000309
atrial fibrillation, valvular heart disease, diabetes mellitus, hypertension and chronic kidney disease. Approximately half of patients are admitted to a cardiology ward but 60% are seen by a cardiologist. Duration of in-hospital treatment varies according to the specialist, with overall median length of stay at 8 days, rising to 9 days under the care of a cardiologist and 12 days under a HF specialist. The prescription of HF disease-modifying agents that block the renin–angiotensin–aldosterone axis remain stable, at 85% for angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers and 52% for mineralocorticoid receptor antagonists, but reassuringly, beta-blocker prescription has increased to 85%. Understandably, prescription of prognostic anti-HF drugs is higher among cardiologists but is increasing among noncardiologists. In-hospital, 30-day and 1-year mortality in the audit remains stable at 9.5, 15 and 34%, respectively, with excess mortality in patients treated on non-medical wards (15 vs 6% cardiology) where prescription of prognostic medications is lower. Predictors of mortality include female sex, renal impairment, tachycardia, hyponatremia and hypo- and hyperkalemia. Reassuringly, all submitting trusts lie within 95% confidence intervals (CIs) on mortality funnel plots suggesting there are no concerning outliers in treatment quality.
Ó 2015 Informa UK Ltd
ISSN 1477-9072
141
Downloaded by [University of Iowa Libraries] at 14:01 05 November 2015
Meeting Report
Chaggar
John McMurray (University of Glasgow, UK) discussed recent breaking trials, the most important of which being PARADIGM-HF [1] which studies a new class of HF drug, the combined angiotensin receptor blocker and neprilysin inhibitor, LCZ696. The neprilysin inhibitor component blocks the degradation of a number of endogenous vasoactive agents, including natriuretic peptides. LCZ696 was compared to enalapril in over 8000 patients with symptomatic HF and EF
ISSN: 1477-9072 (Print) 1744-8344 (Online) Journal homepage: http://www.tandfonline.com/loi/ierk20
British Society for Heart Failure 17th Annual Autumn Meeting Parminder S Chaggar To cite this article: Parminder S Chaggar (2015) British Society for Heart Failure 17th Annual Autumn Meeting, Expert Review of Cardiovascular Therapy, 13:2, 141-143 To link to this article: http://dx.doi.org/10.1586/14779072.2015.1000309
Published online: 02 Jan 2015.
Submit your article to this journal
Article views: 32
View related articles
View Crossmark data
Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierk20 Download by: [University of Iowa Libraries]
Date: 05 November 2015, At: 14:01
Meeting Report
British Society for Heart Failure 17th Annual Autumn Meeting Downloaded by [University of Iowa Libraries] at 14:01 05 November 2015
Expert Rev. Cardiovasc. Ther. 13(2), 141–143 (2015)
Parminder S Chaggar North West Heart Centre, University Hospital of South Manchester, Manchester, UK Tel.: 01 619 987 070 [email protected]
British Society for Heart Failure 17th Annual Autumn Meeting QEII Conference Centre, London, UK, 27–28 November 2014 The British Society for Heart Failure recently held its 17th annual meeting in London, attracting over 700 delegates for the 2-day conference. The meeting covered a wide range of topics, including common co-morbidities, diagnostic dilemmas, latest guidelines/clinical trials and managing clinically challenging scenarios. The British Society for Heart Failure meeting provides an entertaining and informative forum to learn from internationally renowned experts in both the field of heart failure and allied specialties. Future meetings are highly recommended.
The British Society for Heart Failure recently held its 17th annual meeting in London, attracting over 700 delegates for the 2-day conference. Entitled ‘Yesterday’s problems, today’s solutions’, the meeting covered a wide range of topics including common co-morbidities, diagnostic dilemmas, problem drugs and a key-note lecture on the development of the artificial heart by Christian Latremouille (Georges Pompidou European Hospital, Paris, France). Of particular note were updates on latest guidelines/clinical trials and managing clinically challenging scenarios. Guidelines & trials update
Theresa McDonagh (King’s College London, UK) presented as yet unpublished data from the latest incarnation of the National Heart Failure Audit which this year includes data from 97% of NHS trusts in England and 100% in Wales. The current audit adds approximately 55,000 heart failure (HF) admissions to the overall audit, which now includes 240,000 admissions. The findings are similar to previous years with approximately 70% of patients diagnosed with left ventricular systolic dysfunction (LVSD) and the proportion of LVSD being higher in men (77% male vs 60% female). Patients with HF with preserved ejection fraction (EF) are more likely to be women and have comorbidities, including
informahealthcare.com
10.1586/14779072.2015.1000309
atrial fibrillation, valvular heart disease, diabetes mellitus, hypertension and chronic kidney disease. Approximately half of patients are admitted to a cardiology ward but 60% are seen by a cardiologist. Duration of in-hospital treatment varies according to the specialist, with overall median length of stay at 8 days, rising to 9 days under the care of a cardiologist and 12 days under a HF specialist. The prescription of HF disease-modifying agents that block the renin–angiotensin–aldosterone axis remain stable, at 85% for angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers and 52% for mineralocorticoid receptor antagonists, but reassuringly, beta-blocker prescription has increased to 85%. Understandably, prescription of prognostic anti-HF drugs is higher among cardiologists but is increasing among noncardiologists. In-hospital, 30-day and 1-year mortality in the audit remains stable at 9.5, 15 and 34%, respectively, with excess mortality in patients treated on non-medical wards (15 vs 6% cardiology) where prescription of prognostic medications is lower. Predictors of mortality include female sex, renal impairment, tachycardia, hyponatremia and hypo- and hyperkalemia. Reassuringly, all submitting trusts lie within 95% confidence intervals (CIs) on mortality funnel plots suggesting there are no concerning outliers in treatment quality.
Ó 2015 Informa UK Ltd
ISSN 1477-9072
141
Downloaded by [University of Iowa Libraries] at 14:01 05 November 2015
Meeting Report
Chaggar
John McMurray (University of Glasgow, UK) discussed recent breaking trials, the most important of which being PARADIGM-HF [1] which studies a new class of HF drug, the combined angiotensin receptor blocker and neprilysin inhibitor, LCZ696. The neprilysin inhibitor component blocks the degradation of a number of endogenous vasoactive agents, including natriuretic peptides. LCZ696 was compared to enalapril in over 8000 patients with symptomatic HF and EF
